ArticleInflammatory bowel diseases2023
Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting.
Article in Inflammatory bowel diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
TOUR: Tofacitinib Response in Ulcerative Colitis - a Real World Prospective Multi-center Study
MIrikizumab in UC - a Real-woRld prOspective multicenteR Registry
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Effectiveness of tofacitinib in patients with ulcerative colitis: an updated systematic review and meta-analysis of real-world studies.BMJ open gastroenterology · 2024Pooled it
- Herpesviridae Reactivation and Therapeutic Outcomes in Patients with Ulcerative Colitis Treated with Tofacitinib.Journal of clinical medicine · 2026Article
- Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study.Intestinal research · 2026Article
- Advances in the Management of Pediatric Inflammatory Bowel Disease: From Biologics to Small Molecules.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Clinical characteristics of patients with difficult-to-treat ulcerative colitis: a nested case-control study using a Japanese claims database.Intestinal research · 2026Article
- Comparative short-term efficacy of upadacitinib versus tofacitinib for ulcerative colitis: a 24-week real-world study in Japan.Intestinal research · 2026Article
- Tofacitinib for ulcerative colitis in Brazil: a multicenter observational study on effectiveness and safety.BMC gastroenterology · 2025Observational
- Prospective observational study of tofacitinib in ulcerative colitis - analysis of clinical data, fatigue and health-related quality of life during the induction phase.Therapeutic advances in gastroenterology · 2025Article
- Electroacupuncture Regulates Oxidative Stress-Mediated NLRP3/ASC/Caspase-1 Pathway to Inhibit Microglial Activation: Alleviating Neuroinflammation and Depression in IBD.Journal of inflammation research · 2025Article
- Long-term efficacy and safety of tofacitinib in patients with ulcerative colitis: 3-year results from a real-world study.Intestinal research · 2024Article
- Tofacitinib use in ulcerative colitis: An expert consensus for day-to-day clinical practice.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024Article
- Highlights in Ulcerative Colitis From the American College of Gastroenterology 2023 Annual Scientific Meeting: Commentary.Gastroenterology & hepatology · 2023Article
- Risk-Benefit of IBD Drugs: A Physicians and Patients Survey.Journal of clinical medicine · 2023Article
- JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases.Frontiers in medicine · 2023Review
- Effectiveness and Safety of Tofacitinib in the Management of Ulcerative Colitis: A Brazilian Observational Multicentric Study.Crohn's & colitis 360 · 2023Article
- Investigation of the Clinical Remission Course in Ulcerative Colitis from Tofacitinib Induction to Tapering or Withdrawal in Japanese Patients: A Single-Center Retrospective Study.Inflammatory intestinal diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 13 institutions in 1 country.
Funding
Abstract
backgroundTofacitinib is an oral, small-molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Using a novel electronic reporting tool, we aimed to prospectively describe the onset of tofacitinib efficacy during induction therapy in a real-world study.
methodsPatient-reported outcome data (PROs) including the simple clinical colitis activity index (SCCAI), PRO Measurement Identification Systems (PROMIS) measures, and adverse events were collected daily for the first 14 days and at day 28 and 56. Paired t tests and P for trend were utilized to compare changes in SCCAI over time. Bivariate analyses and logistic regression models were performed to describe response (SCCAI <5) and remission (SCCAI ≤2) by clinical factors.
resultsOf all included patients (n = 96), 67% had failed ≥2 biologics, and 61.5% were on concomitant steroids. Starting at day 3, PROs showed significant and persistent decline of the mean SCCAI (-1.1, P < 000.1) including significantly lower SCCAI subscores for stool frequency (-0.3; P < .003), bleeding (-0.3; P < .0002) and urgency (-0.2; P < .001). Steroid-free remission at day 14, 28, and 56 was achieved in 25%, 30.2%, and 29.2% of patients, respectively. Neither prior biologics nor endoscopic severity were independently predictive of response or remission in multivariate models. Numeric improvements in all PROMIS measures (anxiety, depression, social satisfaction) were seen through day 56. Rates of discontinuation due to adverse events were low.
conclusionsIn this prospective real-world study, tofacitinib resulted in a rapid and persistent improvement in UC disease activity PROs. The safety findings were consistent with the established safety profile of tofacitinib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.